策略研究 | 证券研究报告 — 总量点评 2026 年 3 月 1 日 3 月金股组合 中银证券研究部 2026 年 3 月金股 3 月金股组合 中银国际证券股份有限公司 具备证券投资咨询业务资格 策略研究 证券分析师：王君 (8610)66229061 jun.wang@bocichina.com 证券投资咨询业务证书编号：S1300519060003 证券分析师：徐沛东 (8621)20328702 peidong.xu@bocichina.com 证券投资咨询业务证书编号：S1300518020001 策略观点：A 股短期波动中期聚焦国内主线，资源品行情正当时。美以 军事打击伊朗对于全球市场及资产价格的影响取决于行动的目标及持续 性。金价上行有望得到进一步支撑。无论是当下的中东局势还是特朗普 关税政策的反复都为短期市场增加了较高的不确定性因素。而这种不确 定性下的避险情绪将为短期贵金属价格形成有力支撑。目前来看，对于 A 股的影响更多集中在风险偏好层面，中期来看，A 股市场将会回归国内 基本面及政策预期。国内两会即将开幕，A 股短期冲击幅度或小于海外， 节后复工情况、两会前后宏观政策的释放是国内投资者关 ...

智通财经APP讯，科美诊断(688468.SH)发布2025年度业绩快报，报告期内，公司实现营业收入 33,267.86万元，较上年同期下降23.75%;实现归属于母公司所有者的净利润4,440.76万元，较上年同期下 降65.05%。 报告期影响公司经营业绩的主要原因：(1)受体外诊断行业集采在全国范围内深度落地的阶段性影响， 公司主营产品价格承压，主营业务收入同比下降。(2)为增强核心竞争力，公司在产品创新方面保持较 高研发投入。(3)本期确认的政府补助等非经常性损益项目较上年同期减少。 ...

2月25日，润达医疗涨3.79%，成交额7.00亿元。两融数据显示，当日润达医疗获融资买入额6707.20万 元，融资偿还5899.94万元，融资净买入807.26万元。截至2月25日，润达医疗融资融券余额合计6.29亿 元。 融资方面，润达医疗当日融资买入6707.20万元。当前融资余额6.26亿元，占流通市值的6.31%，融资余 额超过近一年50%分位水平，处于较高位。 融券方面，润达医疗2月25日融券偿还0.00股，融券卖出4.43万股，按当日收盘价计算，卖出金额72.83 万元；融券余量16.27万股，融券余额267.48万元，超过近一年90%分位水平，处于高位。 资料显示，上海润达医疗科技股份有限公司位于上海市虹口区乍浦路89号星荟中心1座8楼，成立日期 1999年1月6日，上市日期2015年5月27日，公司主营业务涉及通过自有综合服务体系向各类医学实验室 提供体外诊断产品及专业技术支持的综合服务。主营业务收入构成为：试剂及其他耗材93.50%，仪器 3.70%，软件开发及服务2.67%，其他(补充)0.14%。 截至9月30日，润达医疗股东户数6.48万，较上期减少1.05%；人均流通股9317股 ...

Group 1 - The core viewpoint of the news is that RunDa Medical has seen a stock price increase of 5.25%, reaching 16.85 CNY per share, with a total market capitalization of 10.172 billion CNY [1] - RunDa Medical, established on January 6, 1999, and listed on May 27, 2015, specializes in providing in vitro diagnostic products and professional technical support to various medical laboratories through its comprehensive service system [1] - The revenue composition of RunDa Medical includes 93.50% from reagents and other consumables, 3.70% from instruments, 2.67% from software development and services, and 0.14% from other sources [1] Group 2 - From the perspective of fund holdings, one fund under Dongcai has heavily invested in RunDa Medical, with the Dongcai Vision Growth Mixed Fund A (018088) increasing its holdings by 9,500 shares in the fourth quarter, making it the largest holding in the fund [2] - The Dongcai Vision Growth Mixed Fund A (018088) has a current scale of 10.8951 million CNY and has achieved a year-to-date return of 14.91%, ranking 432 out of 8,880 in its category [2] - The fund manager, Sun Chenyang, has been in position for 2 years and 307 days, with the best fund return during his tenure being 71.92% and the worst being -28.98% [3]

Core Viewpoint - RunDa Medical (603108.SH) has announced a projected net loss for 2025, estimating a loss between 5.65 billion to 4.71 billion yuan, reflecting significant operational challenges due to industry-wide price reductions and macroeconomic pressures [2][3] Financial Performance - The company's net profit for 2023 saw a year-on-year decline of 62.16%, with a further drop of 78.94% in 2024 [2] - For the first three quarters of 2025, the net profit was reported at -1.63 billion yuan, compared to a profit of 50.42 million yuan in the same period last year [2] - Overall revenue decreased by approximately 15% compared to the previous year [3] Industry Challenges - The IVD (in vitro diagnostics) sector is facing challenges due to centralized procurement policies that have led to price reductions, impacting revenue and profit margins [3][7] - The implementation of centralized procurement has resulted in lower product prices and delayed payment cycles from public hospitals, exacerbating financial pressures on the company [3][4] Subsidiary Performance - Some subsidiaries of RunDa Medical have not met profitability expectations, leading to an anticipated goodwill impairment provision of 180 million to 220 million yuan [4] - The company has noted that accounts receivable collection periods have lengthened due to financial pressures on hospitals, although the risk of bad debts remains low [4][5] Business Segments - RunDa Medical's business is divided into three main segments: commercial, industrial, and emerging AI medical services, all of which are experiencing varying degrees of pressure [6] - The commercial segment, which is the main revenue driver, reported a revenue decline of 8.34% in 2024, with further declines in specific areas such as centralized testing services and third-party laboratory services [6] Future Outlook - The company is focusing on AI medical and digital business as future growth areas, with the medical information business showing a 40.73% revenue increase in the first half of 2025 [8] - However, the new business segments are not expected to compensate for the decline in traditional business in the short term [8][9] - RunDa Medical plans to leverage its technological expertise in smart healthcare to enhance its service offerings and operational efficiency [9][10]

Core Viewpoint - RunDa Medical has announced a projected net loss for the fiscal year 2025, estimating a loss between 565 million yuan and 471 million yuan, a significant decline compared to a profit of 55.28 million yuan in the same period last year [1] Group 1: Financial Performance - The company's revenue is expected to decrease by approximately 15% compared to the same period last year due to changes in the domestic macro environment and the implementation of centralized procurement policies in the in-vitro diagnostics industry [1] - The gross profit margin has also experienced a decline, contributing to the overall expected loss [1] Group 2: Cost Management and Operational Challenges - In response to external environmental changes, the company has implemented various cost control and expense management measures to enhance operational efficiency [1] - Fixed costs such as depreciation, amortization, and financing expenses have not decreased in proportion to the revenue decline, impacting overall profitability [1] Group 3: Impairment and Receivables - The company anticipates recognizing goodwill impairment provisions between 180 million yuan and 220 million yuan based on the actual operating conditions of certain subsidiaries, with the final amount subject to audit and evaluation [1] - There has been an extension in the collection period for accounts receivable, leading the company to make credit impairment provisions for related receivables [1]

1. Report Title and Date - The report is titled "Convertible Bond Industry Chain Big Map - February 2026" and was issued on February 3, 2026 [1] 2. Analysts and Contact Information - Analysts are Yang Yewei and Wang Sufang, with their respective license numbers S0680520050001 and S0680524060002, and email addresses yangyewei@gszq.com and wangsufang@gszq.com [2][3] 3. Hot Topics and Related Convertible Bonds 3.1 "Brain - Machine Interface" - Convertible bonds related to this topic include Lepu Convertible Bond 2, Yiwei Convertible Bond, Kelan Convertible Bond, Jiahe Convertible Bond, and Seli Convertible Bond, with details such as their prices, premiums, balances, and associations with the brain - machine interface provided [5] 3.2 "Commercial Spaceflight" (Part 1) - Convertible bonds include Qifan Convertible Bond, Lion Convertible Bond, Ruike Convertible Bond, etc., with information about their industries, prices, and associations with the commercial spaceflight field [7] 3.3 "Commercial Spaceflight" (Part 2) - Convertible bonds like Tian23 Convertible Bond, Guoli Convertible Bond, and Mengsheng Convertible Bond are related, and their details are presented [10] 4. Industry Chains and Related Convertible Bonds 4.1 Power, Electrical Equipment Industry Chain - It includes segments such as power generation, power equipment, and energy storage, with a list of related convertible bonds like Jieneng Convertible Bond, Jinke Convertible Bond, etc. The top 10 convertible bonds by trading volume in January are also provided, including details like trading volume, price, and premiums [13][15] 4.2 Mining, Non - ferrous Metals, and Chemical Industry Chain - Covers various segments such as basic chemicals, chemical fibers, and coal. Related convertible bonds are listed, and the top 10 convertible bonds by January trading volume are presented, including their trading volumes, prices, and other indicators [17][19] 4.3 Machinery, Transportation, and Automobile Industry Chain - Comprises machinery, automobile parts, and logistics segments. Related convertible bonds are listed, and the top 10 convertible bonds by January trading volume are shown, including trading volumes, prices, and premiums [22][24] 4.4 Electronics Industry Chain - Includes semiconductor materials, electronic chemicals, etc. Related convertible bonds are listed, and the top 10 convertible bonds by January trading volume are provided, with details like trading volume, price, and premiums [27][32] 4.5 Military and TMT Industry Chain - Involves communication equipment, military, computer, and media segments. Related convertible bonds are listed, and information about some convertible bonds' trading volume, price, and other aspects in January is presented [35][38] 4.6 Real Estate Industry Chain - Covers building materials, construction engineering, and household appliances segments. Related convertible bonds are listed, and the top 10 convertible bonds by January trading volume are shown, including trading volumes, prices, and premiums [41][46] 4.7 Financial Industry Chain - Divided into non - banking finance and banking segments. All related convertible bonds are listed, and information about their trading volume, price, and other indicators in January is provided [49][52] 4.8 Light Industry and Downstream Consumption Industry Chain - Encompasses papermaking, agriculture, forestry, animal husbandry, and fishery, and other segments. Related convertible bonds are listed, and the top 10 convertible bonds by January trading volume are presented, including trading volumes, prices, and premiums [55][57] 4.9 Pharmaceutical and Biological Industry Chain - Includes pharmaceutical product production, medical devices, and pharmaceutical circulation. Related convertible bonds are listed, and the top 10 convertible bonds by January trading volume are provided, with details like trading volume, price, and premiums [60][64] 4.10 Environmental Protection Industry Chain - Covers environmental monitoring, comprehensive treatment, and waste treatment. Related convertible bonds are listed, and the top 10 convertible bonds by January trading volume are shown, including trading volumes, prices, and premiums [67][69]

Group 1 - The core viewpoint of the news is that RunDa Medical has seen a stock price increase of 5.12%, reaching 16.22 CNY per share, with a trading volume of 284 million CNY and a turnover rate of 2.97%, resulting in a total market capitalization of 9.792 billion CNY [1] - RunDa Medical, established on January 6, 1999, and listed on May 27, 2015, is located in Shanghai and primarily provides in vitro diagnostic products and professional technical support to various medical laboratories through its comprehensive service system [1] - The company's main revenue composition includes reagents and other consumables at 93.50%, instruments at 3.70%, software development and services at 2.67%, and other (supplementary) at 0.14% [1] Group 2 - From the perspective of RunDa Medical's top ten circulating shareholders, Southern Fund's Southern CSI 1000 ETF (512100) reduced its holdings by 48,700 shares in the third quarter, now holding 4.4119 million shares, which accounts for 0.73% of the circulating shares [2] - The Southern CSI 1000 ETF (512100) was established on September 29, 2016, with a latest scale of 78.996 billion CNY, and has achieved a year-to-date return of 4.98%, ranking 1606 out of 5562 in its category [2] - The fund manager, Cui Lei, has a cumulative tenure of 7 years and 90 days, with the fund's total asset scale at 137.02 billion CNY, achieving the best return of 279.97% and the worst return of -15.93% during the tenure [2]

Core Viewpoint - RunDa Medical (603108.SH) is expected to report a net loss attributable to shareholders of the parent company ranging from -565 million to -471 million yuan for the fiscal year 2025, indicating a decline compared to the previous year [1] Group 1: Financial Performance - The projected net profit attributable to shareholders, excluding non-recurring gains and losses, is expected to be between -588 million and -490 million yuan for 2025 [1] - The company's revenue is anticipated to decrease by approximately 15% compared to the same period last year due to changes in the domestic macro environment and the implementation of centralized procurement policies in the in-vitro diagnostics industry [1] Group 2: Operational Challenges - The decline in revenue and gross margin is attributed to the impact of external environmental changes and pricing pressures on products [1] - Despite efforts to enhance management efficiency and implement cost control measures, fixed costs such as depreciation and financing expenses have not decreased in proportion to the revenue decline [1] Group 3: Impairment and Credit Risks - The company expects to recognize goodwill impairment provisions ranging from 180 million to 220 million yuan for certain subsidiaries due to their underperformance [1] - There has been an extension in the collection period for accounts receivable, leading the company to make credit impairment provisions for related accounts [1]

Group 1 - The core viewpoint of the news is that Lanwei Medical has experienced fluctuations in its stock performance and financial metrics, indicating potential investment opportunities and risks in the medical diagnostics sector [1][2]. Group 2 - As of January 29, Lanwei Medical's stock price decreased by 0.52%, with a trading volume of 148 million yuan. The financing buy-in amount was 19.1552 million yuan, while the financing repayment was 13.7929 million yuan, resulting in a net financing buy-in of 5.3622 million yuan. The total financing and securities balance reached 122 million yuan [1]. - The financing balance of Lanwei Medical is 121 million yuan, accounting for 2.65% of its market capitalization, which is above the 90th percentile level over the past year, indicating a high level of financing activity [1]. - On the short-selling side, there were no shares repaid or sold on January 29, with a short-selling balance of 39.79 million yuan, also exceeding the 90th percentile level over the past year [1]. - As of September 30, the number of shareholders for Lanwei Medical was 21,700, a decrease of 6.26% from the previous period, while the average circulating shares per person increased by 6.68% to 16,564 shares [2]. - For the period from January to September 2025, Lanwei Medical reported a revenue of 1.102 billion yuan, a year-on-year decrease of 16.51%. However, the net profit attributable to the parent company was -667,700 yuan, showing a significant year-on-year growth of 98.35% [2]. - Since its A-share listing, Lanwei Medical has distributed a total of 320 million yuan in dividends, with 200 million yuan distributed over the past three years [3].